DTIL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 mai 2024 @ 22:00):

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States...

Stats
Dagens volum	45 075.00
Gjennomsnittsvolum	129 970
Markedsverdi	88.92M
EPS	$0 ( 2024-05-14 )
Neste inntjeningsdato	( $-0.770 ) 2024-08-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.0530 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-08	Amoroso Michael	Buy	8 334	Common Stock
2024-05-08	Kelly John Alexander	Buy	8 334	Common Stock
2024-05-08	Smith J. Jefferson	Buy	833	Common Stock
2024-05-08	Scimeca Dario	Buy	833	Common Stock
2024-05-04	Pire Shari Lisa	Buy	4 202	Common Stock

INSIDER POWER
14.40
Last 100 transactions
Buy: 2 573 781 \| Sell: 1 742 339

Volum Korrelasjon

Lang: -0.05 (neutral)

Kort: 0.58 (weak)

Signal:(50.289) Neutral

Precision BioSciences Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Precision BioSciences Inc Korrelasjon - Valuta/Råvare

0.16
( neutral )

0.17
( neutral )

0.00
( neutral )

0.07
( neutral )

0.68
( moderate )

-0.21
( neutral )

Precision BioSciences Inc Økonomi

Annual	2023
Omsetning:	$48.73M
Bruttogevinst:	$40.47M (83.06 %)
EPS:	$-18.16

FY	2023
Omsetning:	$48.73M
Bruttogevinst:	$40.47M (83.06 %)
EPS:	$-18.16

FY	2022
Omsetning:	$25.10M
Bruttogevinst:	$16.09M (64.12 %)
EPS:	$-41.95

FY	2021
Omsetning:	$115.53M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Precision BioSciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Precision BioSciences Inc

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.